Skip to main content

Table 6 Pearson correlation (bolded) and 95% CIs for baseline log-transformed proteomic markers and baseline log-transformed variables involved in CHD and stroke pathophysiology

From: Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases

CHD and stroke risk factors

Proteomic marker

 

B2M

ORM1

THBS1

CFD

IGFBP1

IGFBP2

IGFBP4

IGFBP6

HPX

Lipids

         

 HDL-C

-0.16

-0.23

-0.10

-0.25

0.22

0.52

-0.25

-0.18

-0.21

(-0.27, -0.05)

(-0.36, -0.09)

(-0.24, 0.06)

(-0.38, -0.11)

(0.08, 0.36)

(0.37, 0.64)

(-0.41, -0.07)

(-0.36, 0.01)

(-0.38, -0.03)

 LDL-C

-0.04

0.04

0.09

-0.01

-0.05

-0.15

0.01

0.02

0.14

(-0.15, 0.08)

(-0.10, 0.19)

(-0.06, 0.24)

(-0.16, 0.13)

(-0.19, 0.10)

(-0.32, 0.04)

(-0.18, 0.19)

(-0.17, 0.21)

(-0.04, 0.32)

Inflammatory markers

         

 CRP

-0.04

0.02

0.12

-0.04

0.05

-0.11

-0.02

-0.04

0.13

(-0.15, 0.08)

(-0.12, 0.17)

(-0.03, 0.27)

(-0.18, 0.11)

(-0.10, 0.19)

(-0.28, 0.08)

(-0.21, 0.16)

(-0.23, 0.15)

(-0.06, 0.30)

 IL-6

0.09

0.30

0.09

0.05

-0.11

-0.16

0.30

0.21

0.23

(-0.03, 0.20)

(0.16, 0.43)

(-0.07, 0.24)

(-0.10, 0.20)

(-0.25, 0.04)

(-0.34, 0.03)

(0.12, 0.46)

(0.01, 0.39)

(0.05, 0.40)

 MMP-9

0.08

0.30

-0.06

0.11

-0.06

-0.20

0.06

0.09

0.07

(-0.03, 0.20)

(0.16, 0.43)

(-0.21, 0.10)

(-0.03, 0.26)

(-0.20, 0.09)

(-0.37, -0.01)

(-0.12, 0.24)

(-0.11, 0.27)

(-0.11, 0.25)

Thrombosis and other blood markers

         

 Factor VIII

0.21

0.14

0.06

-0.02

0.08

-0.11

0.23

0.19

0.12

(0.10, 0.32)

(0.00, 0.28)

(-0.10, 0.21)

(-0.16, 0.12)

(-0.07, 0.22)

(-0.29, 0.08)

(0.05, 0.39)

(0.00, 0.37)

(-0.06, 0.30)

 Factor 1.2

0.01

-0.04

-0.02

0.08

0.09

0.06

-0.02

0.06

0.31

(-0.10, 0.13)

(-0.18, 0.10)

(-0.18, 0.13)

(-0.07, 0.22)

(-0.06, 0.23)

(-0.13, 0.24)

(-0.20, 0.16)

(-0.13, 0.25)

(0.14, 0.47)

 D-Dimer

-0.02

0.15

-0.10

0.08

0.11

-0.04

0.00

0.00

0.15

(-0.14, 0.10)

(0.00, 0.29)

(-0.26, 0.06)

(-0.07, 0.23)

(-0.04, 0.26)

(-0.23, 0.15)

(-0.19, 0.18)

(-0.19, 0.20)

(-0.04, 0.32)

 vWF

0.13

0.22

0.08

0.36

-0.01

0.15

0.18

0.09

0.06

(0.02, 0.24)

(0.07, 0.35)

(-0.22, 0.08)

(0.23, 0.48)

(-0.16, 0.13)

(-0.03, 0.33)

(0.00, 0.35)

(-0.10, 0.28)

(-0.13, 0.24)

 Insulin

0.23

-0.03

-0.01

0.19

-0.04

0.02

0.29

0.23

0.04

(0.12, 0.33)

(-0.17, 0.11)

(-0.16, 0.14)

(0.05, 0.32)

(-0.18, 0.11)

(-0.16, 0.21)

(0.11, 0.44)

(0.04, 0.40)

(-0.14, 0.22)

 Glucose

0.03

0.17

0.02

0.24

-0.44

-0.13

0.29

0.28

0.26

(-0.08, 0.15)

(0.02, 0.31)

(-0.14, 0.17)

(0.10, 0.38)

(-0.55, -0.31)

(-0.31, 0.07)

(0.10, 0.45)

(0.08, 0.45)

(0.07, 0.43)

 WBC

0.01

0.02

0.06

0.02

-0.10

-0.30

0.09

0.21

0.11

(-0.10, 0.12)

(-0.12, 0.17)

(-0.09, 0.21)

(-0.12, 0.16)

(-0.24, 0.04)

(-0.46, -0.12)

(-0.10, 0.27)

(0.02, 0.39)

(-0.08, 0.29)

Blood pressure

         

 Systolic BP

0.08

0.10

0.17

0.04

-0.03

-0.25

0.00

0.17

0.14

(-0.04, 0.19)

(-0.04, 0.24)

(0.02, 0.32)

(-0.11, 0.18)

(-0.17, 0.12)

(-0.42, -0.07)

(-0.18, 0.18)

(-0.02, 0.35)

(-0.04, 0.31)

 Diastolic BP

0.18

0.08

-0.11

0.19

0.00

-0.06

0.18

0.18

0.05

 

(0.08, 0.28)

(-0.06, 0.22)

(-0.25, 0.05)

(0.05, 0.32)

(-0.15, 0.14)

(-0.21, 0.09)

(0.03, 0.32)

(0.03, 0.33)

(-0.10, 0.19)

  1. Correlations are based on data from 357 controls drawn from the placebo groups of the WHI postmenopausal HT trials of estrogen plus progestin and estrogen-alone. Estimated correlations are bolded for ease of viewing.
  2. BP: blood pressure; CRP: C-reactive protein; Factor 1.2: prothrombin fragment 1.2; Factor VIII: clotting factor eight; HDL-C: high-density lipoprotein cholesterol; IL-6: interleukin 6; LDL-C: low-density lipoprotein cholesterol; MMP-9: matrix metallaprotinase-9; vWF: von villebrand factor; WBC: total leukocyte count; WHI: Women’s Health Initiative.